Integrated BioPharma posts $691K quarterly net loss
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Integrated BioPharma, Inc. (INBP) reported revenue of $9.913 million for the quarter ended September 30, 2026, down approximately 22.0% from $12.689 million a year earlier. The company recorded an operating loss of $961,000, compared with operating income of $163,000 in the prior-year quarter, and a net loss of $691,000 versus net income of $123,000.
Diluted loss per common share was $0.02, compared with $0.00 per share a year earlier. The two largest customers in its Contract Manufacturing Segment accounted for approximately 88% of total revenue, versus 87% in the same quarter of 2025.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointRevenue decreased approximately 22.0% to $9.9 million year over year.
- Moderate pointNet result shifted to a $691,000 loss from $123,000 income.
Filing Explained
This 8-K reports completed results for the quarter ended
Sources and calculations
- Integrated BioPharma Form 8-K and Exhibit 99.1 (2026-11-13)
- Integrated BioPharma latest-quarter fundamentals (2027Q1 (period ended 2026-09-30))
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $3,116,000 / ($1,219,000 / 92) = 235.2 days
8-K Event Classification
Key Figures
Key Terms
Contract Manufacturing Segment financial
Gross (loss) profit financial
Forward-looking statements regulatory
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did INBP report for the quarter ended September 30, 2026?
What was INBP's net income or loss for the quarter ended September 30, 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
|
|
|
|
(COMMISSION FILE NUMBER)
|
(I.R.S. EMPLOYER IDENTIFICATION NO.)
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
None
|
None
|
None
|
|
99.1
|
Press Release dated November 13, 2026
|
|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
Exhibit
|
|
Description
|
|
99.1
|
|
Press Release dated November 13, 2026
|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
|
INTEGRATED BIOPHARMA, INC.
|
|
|
Date: November 13, 2026
|
By: /s/ Dina L Masi
|
|
Dina L. Masi
|
|
|
Chief Financial Officer
|
Exhibit 99.1
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026
HILLSIDE, NEW JERSEY (November 13, 2026) - Integrated BioPharma, Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2026.
Revenue for the quarters ended September 30, 2026 was $9.9 million compared to $12.7 million for the quarter ended September 30, 2025, a decrease of $2.8 million or approximately 22.0%. The Company had an operating loss of $1.0 million in the quarter ended September 30, 2026 compared to operating income of $0.2 million for the quarter ended September 30, 2025.
For the quarter ended September 30, 2026, the Company had a net loss of approximately $0.7 million compared to net income of approximately $0.1 million for the quarter ended September 30, 2025 or $(0.02) and $0.00 per share of common stock, respectively. The Company’s diluted net (loss) income per share of common stock for the quarters ended September 30, 2026 and 2025 were $(0.02) and $0.00 per share of common stock, respectively.
“Our revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively,” stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay.
A summary of our financial results for the three months ended September 30, 2026 and 2025 follows:
|
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES |
||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||
|
(In thousands, except share and per share amounts) |
||||||||
|
(unaudited) |
||||||||
|
Three Months Ended |
||||||||
|
September 30, |
||||||||
|
2026 |
2025 |
|||||||
|
Total revenue |
$ | 9,913 | $ | 12,689 | ||||
|
Cost of sales |
10,025 | 11,670 | ||||||
|
Gross (loss) profit |
(112 | ) | 1,019 | |||||
|
Selling and administrative expenses |
849 | 856 | ||||||
|
Operating (loss) income |
(961 | ) | 163 | |||||
|
Other income, net |
38 | 33 | ||||||
|
(Loss) income before income taxes |
(923 | ) | 193 | |||||
|
Income tax (benefit) expense, net |
(232 | ) | 73 | |||||
|
Net (loss) income |
$ | (691 | ) | $ | 123 | |||
|
Basic net (loss) income per common share |
$ | (0.02 | ) | $ | 0.00 | |||
| Diluted net (loss) income per common share | (0.02 | ) | $ | 0.00 | ||||
| Weighted average common shares outstanding - basic | 31,059,610 | 31,059,610 | ||||||
|
Weighted average common shares outstanding - diluted |
31,059,610 | 31,421,338 | ||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. (“INBP”) is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” believes,” intends,” “estimates,” “should,” “would,” “strategy,” “plan” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP’s products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled “Risk Factors” in INBP’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.